Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
Highlights
The company's revenue rose by 46% YoY and by 12% QoQ
Bristol Myers Squibb's gross profit has increased by 44% YoY and by 15% from the previous quarter
The net income has dropped by 159% since the previous quarter and by 109% year-on-year
Bristol Myers Squibb's EPS has shrunk by 144% QoQ and by 107% YoY
Key stats
What are the main financial stats of BMY
Market
Shares outstanding
2.25B
Market cap
$142.54B
Enterprise value
$169.28B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.91
Price to sales (P/S)
4.1
EV/EBIT
67.17
EV/EBITDA
18.89
EV/Sales
4.86
Earnings
Revenue
$34.86B
EBIT
$2.52B
EBITDA
$8.96B
Free cash flow
$12B
Per share
EPS
-$0.28
Free cash flow per share
$5.3
Book value per share
$21.7
Revenue per share
$15.41
TBVPS
$21.36
Balance sheet
Total assets
$128.08B
Total liabilities
$78.92B
Debt
$46.67B
Equity
$49.09B
Working capital
$10.92B
Liquidity
Debt to equity
0.95
Current ratio
1.47
Quick ratio
1.26
Net debt/EBITDA
2.98
Margins
EBITDA margin
25.7%
Gross margin
69.6%
Net margin
-1.6%
Operating margin
7.3%
Efficiency
Return on assets
-0.5%
Return on equity
-1.3%
Return on invested capital
5%
Return on capital employed
2.4%
Return on sales
7.2%
Dividend
Dividend yield
2.78%
DPS
$1.76
Payout ratio
N/A
BMY stock price
How has the Bristol Myers Squibb stock price performed over time
Financial performance
How have Bristol Myers Squibb's revenue and profit performed over time
Revenue
$34.86B
Gross profit
$24.26B
Operating income
$2.54B
Net income
-$563M
Gross margin
69.6%
Net margin
-1.6%
The net income has dropped by 159% since the previous quarter and by 109% year-on-year
BMY's net margin has dropped by 152% since the previous quarter and by 106% year-on-year
The operating margin has dropped by 77% year-on-year and by 16% since the previous quarter
The operating income has dropped by 66% year-on-year and by 6% since the previous quarter
Valuation
What is Bristol Myers Squibb stock price valuation
P/E
N/A
P/B
2.91
P/S
4.1
EV/EBIT
67.17
EV/EBITDA
18.89
EV/Sales
4.86
Bristol Myers Squibb's EPS has shrunk by 144% QoQ and by 107% YoY
BMY's P/B is 52% below its 5-year quarterly average of 6.0 and 3% below its last 4 quarters average of 3.0
The company's revenue rose by 46% YoY and by 12% QoQ
The price to sales (P/S) is 13% less than the 5-year quarterly average of 4.7 but 8% more than the last 4 quarters average of 3.8
Efficiency
How efficient is Bristol Myers Squibb business performance
Bristol Myers Squibb's ROA has plunged by 150% from the previous quarter and by 103% YoY
The ROE has plunged by 146% from the previous quarter and by 103% YoY
BMY's return on invested capital has dropped by 85% year-on-year and by 14% since the previous quarter
Bristol Myers Squibb's return on sales has shrunk by 77% YoY and by 16% QoQ
Dividends
What is BMY's dividend history
DPS
$1.76
Dividend yield
2.78%
Payout ratio
N/A
Recent dividends
Financial health
How did Bristol Myers Squibb financials performed over time
BMY's total assets is 62% greater than its total liabilities
The quick ratio has shrunk by 65% YoY and by 9% QoQ
Bristol Myers Squibb's current ratio has plunged by 62% YoY and by 11% from the previous quarter
BMY's debt is 4.9% smaller than its equity
All financial data is based on trailing twelve months (TTM) periods - updated
quarterly, unless otherwise specified.